Qiagen (QGEN) investor relations material

Strategic leadership, market position, and innovation

• Holds a leading position in sample technologies, foundational to molecular workflows, with a legacy of standardization and innovation spanning 40 years and a 55–60% market share globally.

• Serves research, clinical, forensics, and agriculture markets, addressing a $2 billion+ market with high-value applications in oncology, microbiome, infectious diseases, and biopharma.

• Recognized as the most trusted brand, with 8 out of 10 labs worldwide using its sample technologies and every life science PhD student familiar with its products.

• Collaborates with leading academic, clinical, and pharma institutions, with over 50,000 annual mentions in scientific publications and >15,000 citations in microbiome research.

• The business is a key entry point for cross-selling downstream solutions, increasing share of wallet and recurring revenue.

Product and technology innovation

• Offers over 350 sample kits for any biological sample and a comprehensive automation portfolio for all throughput levels, including QIAcube, EZ2 Connect, QIAsymphony, and upcoming launches like QIAsymphony Connect, QIAsprint Connect, and QIAmini by 2026.

• Drives conversion from manual to automated workflows, with a shift from 60% manual to increasing automation and >100,000 instrument placements targeted.

• New automation platforms target significant market opportunities: QIAsprint Connect (10,000 placements), QIAmini (100,000 placements), and QIAsymphony Connect (5,000+ placements).

• The acquisition of Parse Biosciences positions the business for leadership in the fast-growing single-cell analysis market, expanding into a $2.1 billion market by 2029 and supporting AI-driven drug discovery.

• Integrated ecosystem supports full workflows from sample prep to NGS, dPCR/qPCR, and data analysis.

Growth opportunities and financial outlook

• Net sales reached $642 million in 2024, with a 2025 target of ~$650 million and a 2028 target of at least $750 million at constant exchange rates, driven by automation and high-value applications.

• High-growth segments include liquid biopsy (35%+ annual growth), minimal residual disease, non-invasive prenatal testing, oncology, organ transplant monitoring, and microbiome analysis.

• No significant incremental salesforce investment is expected for new launches, leveraging existing global coverage and anticipating stabilization in academic capital spending.

• Customer feedback from early access field tests is positive, confirming efficiency, throughput, and ease of use for new systems.

• Portfolio strategy focuses on expanding automation, capturing high-growth applications, and investing in new technologies.